Recruited to start up Local Company operations; in-sourcing function from Distributor, including negotiation of the Termination Agreement. Development and implementation of the new organization for the medical devices, proprietary and generic products.
Opened the new legal entity, established the structure and initiated commercial sales in 6 months. Full P&L responsibility and over the first year sales forecast of U$D 10 million; direct responsibility over 17 employees and outsourced services. Reported to the Regional Head Quarters.

Celgene Corporation, 2007 -2010
Global Biopharmaceutical Company
Director of Marketing Oncology Latin America. 2009 - 2010 New Jersey, USA
Developed and managed the regional brand strategies; alignment of corporate guidelines, resources, investment, sales and marketing activities of hematology /oncology products through a distributor network in Latin America. Reported to the Executive Director of Marketing and the GM.
Registration and launch of the hematology / oncology products Revlimid® & Vidaza®. In-market sales of U$D 36 million, over passing the sales budget and with a threefold increment over the first year of commercial sales.
Led and influenced cross-functional teams within the companies, from the registration to the launching of Celgene’s hematologic / oncologic key franchises Revlimid® (lenalidomide) and Vidaza® (azacitidine) for Multiple Myeloma and Myelodysplastic Syndromes in 18 countries.
Prepared the commercial training programs for the Distributors. Supplied the medical & marketing information of the products and approved the promotional materials (in Spanish and Portuguese).
Area Manager of Latin America,(Pharmion SL acquired by Celgene)2007-2008. Madrid, Spain
Start up of the business in Latin America, Marketing representative for the due diligence process to select Distributors and prepare the Distribution Agreement. Development of Brand Strategies and Tactics. Reporting to the Senior Director International Commercial Operations.
Successfully registered and launched Vidaza® in Argentina in only 10 months, becoming the top treatment of the hematology / oncology disease.
Championed Advisory Boards meetings with the Regional Key Opinion Leaders (KOL) and the Chair of an International KOL discussing valuable medical information for accurate and compliant pre-marketing and launch plans.